Travere Therapeutics, Inc.TVTX
What Travere Therapeutics, Inc. does.
Those statements in the following discussion that are not historical in nature should be considered forward-looking statements that are inherently uncertain. Actual results and the timing of the events may differ materially from those contained in these forward-looking statements due to a number of factors, including those discussed in the “Cautionary Statement Regarding Forward-Looking Statements” and “Risk Factors” set forth elsewhere in this Annual Report.
We are a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Our approach centers on advancing our innovative pipeline with multiple late-stage clinical programs targeting rare diseases with significant unmet medical needs.
In September 2024, the U.S. Food and Drug Administration ("FDA") granted full approval to our lead development program, FILSPARI (sparsentan), which is indicated to slow kidney function decline in adults with primary Immunoglobulin A nephropathy (" IgAN") who are at risk of disease progression. IgAN is a rare progressive kidney disease and the most common type of primary glomerulonephritis worldwide. FILSPARI had previously been granted accelerated approval for IgAN in February 2023 based on the surrogate marker of proteinuria. Full approval was based on positive long-term confirmatory results from the PROTECT Study demonstrating that FILSPARI significantly slowed kidney function decline over two years compared to irbesartan.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $198.3M | $131.8M | $109.5M | $145.2M | $233.2M | $490.7M |
| Net income | -$169.4M | -$180.1M | -$278.5M | -$111.4M | -$321.5M | -$25.5M |
| Free cash flow | -$49.5M | -$19.9M | -$186.5M | -$280.7M | — | — |
More on TVTX.
- Travere Therapeutics, Inc. summary
- Travere Therapeutics, Inc. financial statements
- Travere Therapeutics, Inc. key metrics
- Travere Therapeutics, Inc. health scores and style box
- Travere Therapeutics, Inc. earnings
- Travere Therapeutics, Inc. dividends
- Travere Therapeutics, Inc. valuation
- Travere Therapeutics, Inc. ownership and insiders
- Travere Therapeutics, Inc. peers
Figures from Travere Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.